CivicaScript Signs Navitus as Partner; Costco Pharmacies Will Sell Civica Insulin Biosims

$30/vial Could Become The New Normal in 2024My readers may recall that on March 3, 2022, I blogged about concurrent press releases from both Civica, Inc. and the JDRF (see my coverageHERE for original news, followed by more detailed analysis on how it was poised to disrupt the PBM kickback schemeHERE) that its CivicaScripts operating unit plans to enter the U.S. market for insulin biosimilars starting first with the basal insulin analogue insulin glargine, followed by biosimilars of lispro and aspart, which is expected to happen in 2024 assuming it encounters no regulatory delays.The original aim of starting with glargine first was to try and disrupt the severe underlying market dysfunction that has resulted in basal insulin analogues being priced at nearly three-times as much money as prandial insulin analogues are now (in part because the unbranded Lilly and Novo Nordisk products introduced in 2020 had successfully brought prices of prandial insulins down while Sanofi had not done the same with Lantus). However, on June 28, 2022, Sanofi announced (see my coverage of thatHERE) announced a two-pronged approach to not only slash prices of branded-Lantus to a price of $35/vial with aValYOU coupon, but will also introduce an unbranded glargine product aimed at bypassing the entire PBM rebate mess which has worked fairly well for rivals Lilly and Novo Nordisk on selected prandial insulins.Lilly has since revealed to investors during the company ' s most recent quarterly earnings ...
Source: Scott's Web Log - Category: Endocrinology Tags: 2022 Biosimilar biosimilars Civica Civica Rx CivicaRx Costco FDA insulin PBM Source Type: blogs